Boehringer Ingelheim has announced the availability of the first tiotropium-based combination therapy on the PBS for the treatment of chronic obstructive pulmonary disease (COPD). PBS listed from 1 December, Spiolto Respimat combines 5μg of tiotropium and 5μg of olodaterol in the Respimat Soft Mist inhaler. The therapy has been shown to offer improvements beyond tiotropium
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.